Erlotinib (Tarceva) in the treatment of non-selected population
of 1735 patients with  advaced non-small-cell lung cancer
(NSCLC) from Czech Republic

a 2011

Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic

SKŘIČKOVÁ, Jana; Miloš PEŠEK; Pavel ZATLOUKAL; Vítězslav KOLEK; František SALAJKA et al.

Základní údaje

Originální název

Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic

Autoři

Vydání

Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.661

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00052777

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000291769800369

Klíčová slova anglicky

performans status; Advanced NSCLC; erlotinib; Efficacy

Změněno: 15. 9. 2011 13:59, Mgr. Michal Petr

Anotace

V originále

The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.

Citovat

SKŘIČKOVÁ, Jana; Miloš PEŠEK; Pavel ZATLOUKAL; Vítězslav KOLEK; František SALAJKA; Leona KOUBKOVÁ; Milana ZEMANOVÁ; Dimka SIXTOVÁ; Jaromír ROUBEC; Helena COUPKOVÁ; Marcela TOMÍŠKOVÁ; Michal HRNČIARIK; Yvona GRYGARKOVÁ a Michal STICHA. Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.

@proceedings{946757,
   author = {Skřičková, Jana and Pešek, Miloš and Zatloukal, Pavel and Kolek, Vítězslav and Salajka, František and Koubková, Leona and Zemanová, Milana and Sixtová, Dimka and Roubec, Jaromír and Coupková, Helena and Tomíšková, Marcela and Hrnčiarik, Michal and Grygarková, Yvona and Sticha, Michal},
   booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer},
   keywords = {performans status; Advanced NSCLC; erlotinib; Efficacy},
   language = {eng},
   title = {Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic},
   year = {2011}
}

TY  - CONF
ID  - 946757
AU  - Skřičková, Jana - Pešek, Miloš - Zatloukal, Pavel - Kolek, Vítězslav - Salajka, František - Koubková, Leona - Zemanová, Milana - Sixtová, Dimka - Roubec, Jaromír - Coupková, Helena - Tomíšková, Marcela - Hrnčiarik, Michal - Grygarková, Yvona - Sticha, Michal
PY  - 2011
TI  - Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic
KW  - performans status
KW  - Advanced NSCLC
KW  - erlotinib
KW  - Efficacy
N2  - The human epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) erlotinib (Tarceva) is approved for use in advanced, pretreated NSCLC. This analysis presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.
ER  -

SKŘIČKOVÁ, Jana; Miloš PEŠEK; Pavel ZATLOUKAL; Vítězslav KOLEK; František SALAJKA; Leona KOUBKOVÁ; Milana ZEMANOVÁ; Dimka SIXTOVÁ; Jaromír ROUBEC; Helena COUPKOVÁ; Marcela TOMÍŠKOVÁ; Michal HRNČIARIK; Yvona GRYGARKOVÁ a Michal STICHA. Erlotinib (Tarceva) in the treatment of non-selected population of 1735 patients with advaced non-small-cell lung cancer (NSCLC) from Czech Republic. In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. 2011. ISSN~1556-0864.

Přehled o publikaci